HK1129562B - Dms (derma membrane structure) in foaming creams - Google Patents

Description

Technical field of the invention

The present invention relates to cosmetic and dermatological foam formulations, in particular foam creams, based on emulsions, in particular of the oil-in-water type, where the oil phase includes at least one membrane-forming substance that forms a lamellar membrane in the foam formula.

Background to the invention The following are emulsions:

Emulsion is generally understood to be a heterogeneous system consisting of two liquids that are not or only limitedly miscible with each other, commonly called phases.

If the two liquids are water and oil and oil droplets are finely dispersed in water, then it is an oil-in-water emulsion (O/W emulsion, e.g. milk).

In order to achieve the permanent dispersion of one liquid into another, emulsions in the conventional sense require the addition of a boundary active substance (emulsifier). Emulsifiers have an amphiphilic molecular structure consisting of a polar (hydrophilic) and an unpolar (lipophilic) molecular part that are spatially separated from each other. In simple emulsions, the one phase contains enemy droplets, surrounded by an emulsifier shell, of the second phase (water droplets in W/O or lipid vectors in O/W emulsions).

Conventional emulsifiers can be divided into ionic (anionic, cationic and amphoteric) and non-ionic according to their hydrophilic molecular fraction: The most well-known example of an anionic emulsifier is soap, which is usually called the water-soluble sodium or potassium salts of saturated and unsaturated higher fatty acids.Important representatives of cationic emulsifiers are the quaternary ammonium compounds.The hydrophilic molecular part of non-ionic emulsifiers is often composed of glycerin, polyglycerin, sorbitans, carbohydrates and polyoxyethylene glycols, and is most often linked to the lipophilic molecule via ester and ether bonds.This is usually composed of fatty alcohols, fatty acids or isopeptides.

By varying the structure and size of the polar and nonpolar molecules, the lipophilia and hydrophilia of emulsifiers can be altered to a large extent.

The stability of a conventional emulsion depends on the correct choice of emulsifiers, which take into account the characteristics of all the substances in the system. For example, when considering skin care emulsions, polar oil components such as UV filters can cause instabilities.

Emulsions are an important product type in cosmetic and/or dermatological products, used in a wide variety of applications. A wide range of products, such as lotions and creams, are available for skin care, particularly for re-oiling dry skin. The purpose of skin care is to compensate for the loss of fat and water from daily washing. Skin care products are also intended to protect against environmental influences, especially sun and wind, and to delay skin aging.

Cosmetic emulsions are also used as deodorants, which are designed to remove body odor caused by the breakdown of fresh, odorless sweat by microorganisms.

Emulsions in the form of cleaning emulsions are also used to clean the skin and skin lesions. They are mostly used for facial cleaning and in particular for removing decorative cosmetics.

The following is the list of emulsions:

For decades, conventional emulsifiers have been the basis for the development of skin care products. Emulsifiers have been used as aids to the manufacture and especially the stabilization of emulsions. Recently, there is evidence that the use of emulsifiers in skin care products can cause problems, for example in sensitive skin, as the emulsifiers typically disrupt the integrity of the natural skin barrier and thus can result in a loss of natural skin barrier substances when skin cleansing. The loss of natural barrier substances can cause increased smoking, dry skin, cracking and wear eczema.

Err1:Expecting ',' delimiter: line 1 column 238 (char 237)

A special form of emulsion is emulsifier-free emulsions, which are free from emulsifiers in the strict sense, i.e. amphiphilic substances with low molar mass (molar mass < 5000) which can form mycellae and/or other liquid crystalline aggregates at appropriate concentrations.

Pickering emulsions are solid-stabilized emulsions in which the finely distributed solid particles stabilize the emulsion, so that conventional emulsifiers can be largely omitted. This results in an enrichment of the solid at the oil/water phase boundary in the form of a layer, thus preventing a convergence of the dispersed phase. Such suitable solid emulsifiers are particulate inorganic or organic solids that are usable by both lipophilic and hydrophilic liquids.

However, these solid emulsifiers can also cause irritation or even allergies in sensitive skin.

Cream formulations are already used today, which work with a variety of natural or skin-like ingredients, which promise better skin tolerance, especially in sensitive skin. It has been shown that the use of skin-like ingredients can achieve improved skin care. For example, in these cream formulations, some components of natural skin lipids such as triglycerides are replaced by (vegetable) caprylic acid/cyprinic acid triglycerides, squalene by (vegetable) squalan, ceramide by hephamide 3 (from he), cholesterol by (vegetable) phytosterols and cerospholipids (vegetable) phospholipids.

This approach preferably avoids many common excipients such as fragrances, dyes, comedogenic lipids (e.g. mineral oils), preservatives and physiologically questionable emulsifiers, as these are potentially sensitising and can cause skin irritation.

These formulations are preferably prepared without conventional emulsifiers to avoid the above-mentioned disadvantages of conventional emulsifiers.

Without relying on any specific theory, it is believed that the special effect of these specifically composed membrane lipids is related to the lamellar structure. The absence of conventional emulsifiers prevents the formation of micelles or vesicles, so that the lamellar structure of the formed membrane is preserved in the emulsion.

Err1:Expecting ',' delimiter: line 1 column 191 (char 190)

The use of foam formulations

Foams are a complex physical structure that requires a special coordination of the foam-forming components. Foams are generally obtained by spraying an emulsion formulation or a water-based Druid stabilizer solution. For example, the foam emulsion is produced with insulated fuel but is released under pressure-resistant systems (in particular, the emulsion is dispersed in a gas and aerosol system, which can also be called a gas and a gas expander).

The advantage of these mesh structures is that they provide a protective function, for example against contact with water, but allow for unimpeded gas exchange with the environment. In such foams, there is practically no obstruction of the perspiration of the insensitive and no corresponding heat block. This combines the positive properties of a protective and caring function with an unchanged skin tone.

The foam formulations known to date contain conventional surfactants/emulsifiers which provide the emulsion stabilisation and subsequent foam stability.

However, as discussed above, conventional emulsifiers or surfactants are repeatedly cited as a cause of intolerance in skin care products, such as skin barrier disorders or acne.

Therefore, there is a need for individual skin care formulations that better meet the needs of the skin than traditional emulsion systems based on emulsifiers and thus provide better skin protection and improved skin care.

The use of cream bases with a lamellar structure in the composition has not been described in foam formulations.

The present invention is intended to provide improved foam formulations, in particular better foam creams, which bypass the above-mentioned disadvantages of the state-of-the-art formulations.

Summary of the invention

Surprisingly, the applicant has found that emulsions comprising an oil phase and a water phase, where the oil phase contains at least one membrane-forming substance that forms a lamellar membrane in the foam formulation, are suitable as a basis for foam formulas.

This combines the positive properties of the foam formulations with those of the emulsions in which the oil phase contains at least one membrane-forming substance which forms a lamellar membrane in the foam formula. In particular, foam formulations can be produced which combine the positive properties of the foam, namely the physical structure and the pleasant usability with a good skin compatibility. This property allows the use of foam formulations for cosmetic and dermatological formulations used on sensitive skin types. The advantageous combination of tolerance and application, which is important for skin compatibility, has not been taken into account in the foam formulations of at least one membrane-forming substance.

It is not self-evident that these emulsions produce stable foam products when foamed. Foams are obtained, as already mentioned, for example by incorporating propellant gases into O/W emulsion systems. When the propellant gas dissolved in the dispersive oil phase evaporates during the foaming process, a foam (gas in liquid dispersion) is formed. When the propellant gas dissolved in the dispersive oil phase is evaporated or expanded, the dispersive oil phase is dilated.

The invention relates to foam formulations comprising an oil phase and a water phase, where the oil phase includes at least one membrane-forming substance that forms a lamellar membrane in the foam formula, which includes at least one membrane-forming substance a lipid, where the lipid includes hydrated lecithin.

The invention preferably relates to foam formulations based on natural or skin-like ingredients which allow for improved skin tolerance.

The invention also relates to the use of the foam formulations described above based on emulsions as carriers for active substances, skin care products or skin cleansers, and the foam formulations may therefore be used as cosmetics, medical devices or medicinal products.

The invention also includes a method for the production of the foam formulations described above based on emulsions in which the oil phase contains a membrane-forming substance which forms a lamellar membrane in the foam formula. (a) Prepare an emulsion preferably of the oil type in water (b) Fill the emulsion and propellant gas in a pressure vessel, or

Detailed description of the invention

According to the present invention, foam formulations are formulations, in particular emulsions, which are purposefully prepared to produce foam. In particular, the formulations may be filled with propellant gas in a pressure vessel or filled without propellant gas in a container other than a pressure vessel, which allows foam to be produced when the formula/emulsion is delivered.

In a preferred embodiment, the foam formulation is a foam cream.

According to the present invention, essentially emulsifier-free emulsions are emulsions containing no more than 1.5% by weight, preferably no more than 1.0%, preferably no more than 0.5% by weight of conventional emulsifiers.

According to the present invention, a membrane-forming substance that forms a lamellar membrane is a substance that has both a hydrophilic and a hydrophobic molecular residue, preferred being substances such as (mono-, di-, tri-) glycerides, lecithins, sphingolipids, phospholipids, ceramides, cholesterol, squalene, squalanes, fatty alcohols, fatty acids and their mono- and/or diester, sterols, etc.

According to the present invention, a lamellar membrane is arranged in such a way that it has a layered structure such that the upper layer of the substance is aligned with a lower layer of the substance, and the individual layers of the substance are aligned with each other independently of the solvent used, e.g. the hydrophilic residues of the substance are outward and the hydrophobic residues are inward, or vice versa.

If two layers of the substance are oriented in the above sense, then one speaks of a single membrane, while in the case of an arrangement of two more layers this lamellar structure is called a double membrane. According to the present principle, further layers can be associated with the already existing (double) membrane, which leads to a multi-membrane structure. According to the present invention, the membrane can be present as a single membrane, as a double membrane or as a multiple membrane.

Err1:Expecting ',' delimiter: line 1 column 53 (char 52)

According to the present invention, body-identical fats, fats present in the body, are of vegetable origin.

Oil phase:

Suitable components that can form the oil phase can be selected from the polar and nonpolar oils or their mixtures.

The oil phase of the formulations according to the invention is preferentially selected from the group of lecithins, (mono-, di-, tri-) glycerides (such as fatty acid triglycerides), sphingolipids, phospholipids, from the group of propylene glycols or butylene glycols, fatty acid esters, from the group of natural waxes of animal and vegetable origin, from the group of esters, from the group of dialkyl ethers and dialkyl carbonates, from the group of branched and unbranched hydrocarbons and waxes, and from the group of cyclic and linear silicone oils.

Err1:Expecting ',' delimiter: line 1 column 779 (char 778)

Err1:Expecting ',' delimiter: line 1 column 112 (char 111)

The membrane-forming substance contains a lipid which contains hydrated lecithin.

In a preferred foam formulation of the invention, the membrane-forming substance also includes a triglyceride.

The preferred foam formulations of the invention may also contain additional components such as stabilizers such as alcohols or glycols, preferably glycols, especially propylene glycol, caprylyl glycol or mixtures thereof.

In preferred foam formulations of the invention, additional ingredients such as Butyrospermum Parkii (Shea butter), Squalan, Gylcerides, Ceramides, preferably Ceramid 3, or mixtures thereof may be incorporated.

A preferred foam formulation of the invention comprises an essentially emulsifier-free emulsion.

Err1:Expecting ',' delimiter: line 1 column 87 (char 86)

The DMS® basic formulations may contain the following components: caprylic acid/capric acid triglyceride, shea butter, squalan, ceramid 3, hydrated lecithin, palm glyceride, Persea gratissima, palm oil (Elaesis guineensis).

For example, alcohols or glycols such as pentilenglycol, caprylyl glycol or mixtures thereof may be used as stabilisers in DMS® formulations.

A commercially available DMS® base includes caprylic acid/capric acid triglyceride, shea butter, squalan, ceramid 3, hydrated lecithin and pentylene glycol.

Another commercially available DMS® base includes: Other Caprylic acid/capric acid triglyceride, shea butter, squalan, ceramid 3, hydrated lecithin and alcohol.

Another commercially available DMS® base includes caprylic acid/caprylic acid triglyceride, shea butter, squalan, ceramid 3, hydrated lecithin, Persea Gratissima and caprylyl glycol.

Another commercially available DMS® base includes caprylic acid/capric acid triglyceride, shea butter, squalan, ceramid 3, hydrated lecithin, palmglycerides, Elaesis guineensis and pentylene glycol.

A preferred DMS® base includes caprylic acid/capric acid triglyceride, butyrospermum parkii, squalan, ceramid 3, hydrated lecithin and pentylene glycol.

A particularly preferred caprylic acid/capric acid triglyceride is available under the name Miglyol 812 from Sasol and its blending with other oil and wax components.

In addition, the preferred product is caprylic acid/capric acid triglyceride, known as Miglyol 812 from Sasol/Myritol 312 from Fa. Cognis.

The emulsions of the invention contain preferably 5% to 50% by weight of oil phase, preferably 10% to 35% by weight and preferably 15% to 35% by weight of oil phase.

These cream formulations are used in particular for irritated, dry to very dry, sensitive to very sensitive, allergic and eczemic skin.

In addition, the oil phase may preferably contain additional components such as fatty acids, particularly stearic acid, or oils such as Cetiol V.

In the case of DMS concentrates and formulations of the invention, it is preferable to exclude other common (non-body identical) excipients such as fragrances, colours, comedogenic lipids (e.g. mineral oils) and physiological emulsifiers, as these are potentially sensitising and may cause skin irritation.

Water phase:

The aqueous phase may contain cosmetic aids, e.g. low alcohols (e.g. ethanol, isopropanol), low diols or polyols and their ethers (e.g. propylene glycol, glycerin, butylene glycol, hexylene glycol and ethylene glycol), foam stabilizers and thickeners.

Suitable thickeners are polymer thickeners that are partially water-soluble or at least dispersed in water and form gels or viscous solutions in aqueous systems. They increase the viscosity of water by either binding water molecules (hydration) or absorbing and enveloping the water into its intertwined macromolecules, thereby limiting the mobility of water. Suitable polymers are: ■ Modified natural substances such as cellulose ethers (e.g. hydroxypropylcellulose ether, hydroxyethylcellulose and hydroxypropylmethylcellulose ether);■ Natural compounds such as agar-agar, carrageenan, polyosenes, starch, dextrins, gelatin, casein;■ Synthetic compounds such as vinyl polymers, polyethers, polyimines, polyamides and derivatives of polyacrylic acid; and■ Inorganic compounds such as polykesic acid and clay minerals.

A cellulose ether is preferably included as a thickener in the formulation of the invention. Hydroxypropylmethylcellulose is particularly preferred. A hydroxypropylmethylcellulose is preferably metolose 90SH100.

Another preferred thickener is xanthan gum, in particular Keltrol® CG xanthan gum.

The hydroxypropylmethylcellulose and xanthan gum may also be used side by side in the formulations of the invention.

The emulsions of the invention contain preferably between 0.2% and 3.0% by weight of thickening agent (based on the dry weight of the thickening agent and the total weight of the emulsion without the propellant gas).

The active substances:

The active substance can be pure plant or synthetic. The active substance group can also overlap with the other active substance groups, such as the oil component, the thickening agents or the solid emulsifiers. For example, some oil components can also serve as more active substances, such as oils with more unhealthy fluids, or UV particulate matter. The solids can be used as particulate filters, depending on the properties of the substance.

The active substances of the formulations of the invention are favorably selected from the group of substances with moisturising and barrier-strengthening properties, such as hydrovitone, a replica of NMF, pyrrolidone carbonic acid and its salts, lactic acid and its salts, glycerol, sorbitol, propylene glycol and urea, substances from the group of proteins and protein hydrolysates such as collagen, elastin and silk protein, substances from the group of aminoglucans, e.g. hyaluronic acid, a subset of the group of carbohydrates, e.g. polyvitamin B, which is similar in composition to the human lipid carbohydrate, glycerol, sorbitol, propylene glycol and urea, substances from the group of proteins and protein hydrolysates such as collagen, elastin and silk protein, substances from the group of aminoglucans, e.g. pentacoccal amino acids, e.g. polyvitamin B, which are in their composition similar to the human lipid carbohydrate, and pantothenol, and C. In addition, other substances such as vitamin A, vitamin B, and vitamin C, can be obtained from the group of the present vitamin, such as the vitamin A, and its vitamins, and its esters, and its derivatives.

It is also preferable to use substances with skin-soothing and regenerative effects, such as panthenol, bisabolol and phytosterols.

Beneficial active substances within the meaning of the present invention include plants and plant extracts, including algae, aloe, arnica, bark nettles, legweed, birch, bramble, calendula, oak, ivy, hamamelis, henna, hops, chamomile, mouse thorn, peppermint, marigold, rosemary, sage, green tea, tea tree, box straw, thyme and walnut and their extracts.

The preparations of the invention may also contain as active substances antifungals and antiseptics/disinfectants of synthetic or natural origin.

Other active substances are glucocorticoids, antibiotics, analgesics, antiphlogistic, anti-rheumatic, antiallergic, antiparasitic, antipruriginose, antipsoriatic, retinoids, local anaesthetics, venous therapeutics, keratolytics, hyperemissing substances, coronary therapy (nitrate/nitro compounds), virostatics, cytostatics, hormones, wound healing agents such as growth factors, enzyme preparations and insecticides.

Other components of the emulsion:

The formulations may also optionally contain colouring matters, gloss pigments, fragrances/perfumes, light-protecting filters, preservatives, complexing agents, antioxidants and repellents and pH regulators.

The foam formulations of the invention may contain, in addition to the ingredients already mentioned, other natural fats, such as shea butter, neutral oils, olive oil, squalene, ceramides and moisturizers, as is common in the art.

The above list of individual components of the emulsion should be understood as meaning that individual sample components can be grouped into several groups due to their different properties.

Fuel gases:

The finished foam formulation contains about 5 to about 15% by weight of propellant, preferably about 10% by weight of propellant.

Manufacture from materials of any heading, except that of the product

The foam formulations of the invention are prepared by providing an emulsion, preferably of the oil-in-water type, and filling the emulsion and, if necessary, infusing it with propellant gas into a suitable container, such as a pressure vessel.

In particular, the emulsions of the invention shall be prepared by a process involving the following steps: (1) Provide an oil phase, if necessary, including at least one membrane-forming substance that forms a lamellar membrane in the formulation,(2) Provide a water phase,(3) Combine and homogenise the two phases,(4) Add at least one or at least one additional membrane-forming substance,(5) Homogenise to obtain an emulsion, optionally Other where at least one of the steps (1) or (4) contains at least one membrane-forming substance that forms a lamellar membrane in the formulation.

The oil phase and the water phase are preferably mixed and homogenised at a temperature of about 40 to about 90 °C each, a temperature of about 60 to about 80 °C being particularly preferred, and a temperature of about 70 °C being more preferable.

Homogenization can be carried out by any means or method known to the art, preferably by homogenization of the phases by a high-pressure stirrer.

In a preferred manufacturing process, the oil phase is mixed with the water phase and homogenised; if necessary, the emulsion is cooled to room temperature by stirring; in a particularly preferred process, an appropriate amount of DMS® concentrate is added to this mixture and incorporated into the emulsion.

DMS® concentrate may be added to the oil phase before homogenisation with the water phase or added to the mixture after homogenisation of the oil and water phase.

If the emulsion contains a thickener, the procedure preferably includes the following additional steps: (6) Prepare a thickening solution in water (7) Mix the thickening solution with the emulsion

The emulsion according to the invention is preferably charged with approximately 10% by weight of propellant gas.

Other uses:

The foam formulations of the present invention can be used for all cosmetic and dermatological purposes (as a medical device or medicine), for example, as skin care products or skin cleansers, as carriers for active substances and in the medical dermatological field, and in particular as sunscreens.

Examples: Composition of the foam formulation:

(a) Water phase Other The water phase is produced by mixing the components. Other

Bestandteil	Menge
HPMC (Metolose 90SH100)	1,5 g
Xanthan Gummi (Keltrol® CG)	0,5 g
Wasser	78 g

Other (b) Oil phase

Example 1:

Bestandteil	Beispiel 1
DMS Konzentrat	5 g
Miglyol 812	14 g
Stearinsäure	1 g
Wasserphase	ad 100 g

Example 2:

Bestandteil	Beispiel 2
DMS Konzentrat	5 g
Miglyol 812	14 g
Stearinsäure	1 g
Cetiol V	5 g
Wasserphase	ad 100 g

The stearic acid is dissolved at approximately 70 °C in miglyol 812 (Example 1) or in the mixture of miglyol 812 and cetyl V (Example 2).

This oil phase is mixed with the water phase and homogenised by a high-turin agitator, the resulting emulsion is cooled to room temperature by stirring and the DMS® concentrate is incorporated by a high-turin agitator.

The DMS® concentrate used has the following INCI components: Aqua (and) Hydrogenated Lecithin (and) Caprylic/Capric Triglycerides (and) Pentylene Glycol (and) Butyrospermum Parkii (and) Glycerin (and) Squalane (and) Ceramide 3 The substance is used as a solvent in the manufacture of other products.

Manufacture of foam formula:

90 g of the emulsion thus obtained are filled in aerosol containers and, after closing, are filled with a 10 g propellant valve lid.

Claims (20)

1. Foam formulation comprising an emulsion which comprises an oil phase and a water phase, wherein the oil phase comprises at least one membrane-forming substance forming a lamellar membrane in the foam formulation, the at least one membrane-forming substance comprises a lipid, wherein the lipid comprises hydrogenated lecithin.
2. Foam formulation according to claim 1, wherein the emulsion is an oil-in-water emulsion.
3. Foam formulation according to anyone of claims 1-2, wherein the lipid comprises a triglyceride.
4. Foam formulation according to claim 3, wherein the triglyceride comprises caprylic acid/caprinic acid triglyceride.
5. Foam formulation according to any one of claims 1-4, wherein the emulsion further comprises at least one thickening agent preferably selected from the group consisting of hydroxypropylmethyl cellulose, xanthan, and mixtures thereof.
6. Foam formulation according to any one of claims 1-5, wherein the emulsion further comprises a stabilizer, wherein the stabilizer is pentylene glycol.
7. Foam formulation according to any one of claims 1-6, wherein the emulsion further comprises conventional components such as shea butter, glycerol, squalan, ceramide, preferably ceramide 3 or mixtures of the aforementioned.
8. Foam formulation according to any one of claims 1-7, wherein the emulsion further comprises conventional components such as oils and lubricating substances.
9. Foam formulation according to anyone of claims 1-8, wherein the emulsion further comprises at least one active agent.
10. Foam formulation according to claim 9, wherein the active agent is selected from the group consisting of hydroviton, pyrrolidone carbonic acid and salts thereof, lactic acid and salts thereof, glycerol, sorbitol, propylene glycol, urea, collagen, elastin, silk protein, hyaluronic acid, pentavitin, ceramides, panthenol, niacin, α-tocopherol and esters thereof, vitamin A, vitamin C, galates, polyphenols, panthenol, bisabolol, phytosteroles, glycocorticoides, antibiotics, analgetics, antiphlogistics, antirheumatics, antiallergics, antiparasitatics, antipruriginosics, antipsoriatics, retinoids, local anaesthetics, therapeutic agents for the veins, ceratolytics, hyperemisic compounds, coronary therapeutics (nitrates/nitro-compounds), virus statics, cytostatics, hormones, agents promoting wound healing, growth factors, enzyme preparations, insecticides and plant material such as e.g. plant extracts of algae, aloe, arnica, barber's rash, comfrey, birch, stinging nettle, calendula, oak, ivy, witch hazel, henna, hops, camomile, ruscus, peppermint, marigold, rosemary, sage, green tea, tea tree, horsetail, thyme and walnut or mixtures thereof.
11. Foam formulation according to anyone of claims 1-10, wherein the lipid comprises bioidentical fats.
12. Foam formulation according to any one of claims 1-11, wherein the formulation is a foam cream.
13. Use of a foam formulation according to any one of claims 1-12, as a skin care agent.
14. Use of a foam formulation according to any one of claims 1-12, as a skin cleaning agent.
15. Use of foam formulation according to any one of claims 1-12 for the manufacture of a cosmetic agent, medical agent of pharmaceutical composition.
16. Method for producing a foam formulation according to any one of the preceding claims, comprising the following steps:

    a) Producing an emulsion, preferably of the oil-in-water type,

    b) Filling the emulsion and propellant into a pressurized container, or

    c) Filling the emulsion into a container other than a pressurized container that upon dispensing of the emulsion generates a foam.
17. Method according to claim 16, wherein producing of the emulsion comprises the steps:

    1) Providing an oil phase optionally comprising at least one membrane-forming substance that forms a lamellar membrane in the formulation,

    2) Providing a water phase,

    3) Adding and homogenizing of both phases,

    4) Optionally adding at least one or at least one further membrane-forming substance,

    5) Optionally homogenizing, in order to obtain an emulsion,

    wherein in at least one of the steps (1) or (4) at least one membrane-forming substance is comprised that forms a lamellar membrane in the formulation.
18. Method according to claim 17, wherein the oil phase and the water phase are homogenized at a temperature between about 40 up to about 90°C, preferably between about 60 up to about 80°C, more preferably at a temperature of about 70°C.
19. Method according to any one of claims 17 or 18, wherein the emulsion comprises a thickening agent, further comprising the steps:

    6) Providing an aqueous solution of thickening agent,

    7) Mixing the solution of thickening agent with the emulsion.
20. Method according to any one of claims 18-19, wherein the foam formulation contains 10 weight percent propellant.